Virtual Library
Start Your Search
L. Yu
Author of
-
+
P2.01 - Advanced NSCLC (ID 618)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:00 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.01-033 - Leptomeningeal Metastasis from Non-Small Cell Lung Cancer: A Single Center Experience in Chinese Patients (ID 9187)
09:00 - 09:00 | Author(s): L. Yu
- Abstract
Background:
Leptomeningeal carcinomatosis（LM）is a rare type of metastatic tumors of the central nervous system. In recent years, with the improvement of neoplasms therapies and longer survival of patients by better systemic control , incidence of LM has increased every year.The incidence of LM in patients with non-small cell lung cancer（NSCLC） ranges from 1%-5%.However, no standard therapy has been established yet.This study is to investigate the clinical characteristics and prognostic factors of LM from NSCLC and to develop better treatment strategies.
Method:
We collected and reviewed retrospectively the clinical characteristics,treatment methods as well as the outcomes of 45 consecutive patients with LM from NSCLC diagnosed and treated in our hospital from 2002 to 2017.Survival rates were analyzed using the Kaplan-Meier method.The multi-variate Cox proportional hazards model was used to determine the independent prognostic factors associated with improved survival.
Result:
Figure 1Among 45 patients who were enrolled, 7(15.6%) had EGFR 19 deletion, 2(4.4%) had EGFR 20 mutation, 22(48.9%) had EGFR 21 mutation, 1(2.2%) had EGFR 18 and also EGFR 20 mutation(T790M negative), 2(4.4%) were ALK-positive, 5(11.1%) were EGFR wild-type, 6(13.3%) patients didn't perform EGFR test. The median overall survival from the diagnosis of LM for all the patients was 15（range, 1–34）months. Gender, gene mutation and Tyrosine kinase Inhibitors (TKIs) treatment were correlated with survival time for the patients(P<0.05 for all). Other prognostic variables such as age, initial ECOG, time to leptomeningeal dissemination, CSF cytology, CSF pressure, CSF biochemical, brain radiotherapy, chemotherapy and intrathecal chemotherapy were not statistically correlated to overall survival. In the multivariate analysis, Cox proportional hazard regression showed that TKIs treatment was the independent prognostic factor(P<0.05).
Conclusion:
TKIs treatment was the independent prognostic factor for leptomeningeal metastases from non-smalll cell lung cancer. We suggest that in LM patients from NSCLC giving TKIs treatment may prolong survival.
